At a glance
ClinicalIndex Comparison RecordN/ACompleted· 7,873 enrolled
Drug / intervention
No Interventionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes in the Real World Setting (VEDO TDM RWE)
In Brief
An observational study evaluating No Intervention for Inflammatory Bowel Diseases and 2 related conditions. Completed, enrolled 7,873 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if a relationship exists between Week 6 vedolizumab therapeutic drug monitoring (TDM) and Week 30 Faecal calprotectin (FCP).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesCanada
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartOct 2020
Primary CompletionSep 2021
TodayJul 2026
First PostedSep 28, 2020
Enrollment StartOct 5, 2020
Primary CompletionSep 22, 2021
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 5.8 years ago
Interventions
No Interventionother
As this was an observational study, no intervention was administered.